DoH – Abu Dhabi, French pharma firm Sanofi announce collaboration

The Department of Health – Abu Dhabi (DoH) has signed a Declaration of Collaboration with French healthcare firm, Sanofi.

Signed in Boston as part of the Abu Dhabi Life Science Mission to US, both parties seek to collaborate in four strategic healthcare priorities, including hematology and oncology, rare metabolic diseases, diabetes management and vaccines.

The agreement includes  cooperation to launch a clinical research project and patient recruitment protocol. The entities will also pursue the creation of data generation and population research projects for late-stage breast cancer, liquid tumors and blood disorders.

Sanofi will support in the launch of a clinical research project and patient recruitment protocol as well as participate in DoH’s Cancer Advisory Group to develop policies significant to the elderly cancer-patient community.

Both organisations will co-create a high-risk population screening project that will support in the detection of rare metabolic diseases utilising artificial intelligence tools. They will also cooperate to integrate the digital healthcare solutions, including MyStar Space, into Abu Dhabi healthcare facilities, and study the outcomes and impact of Type II diabetes management.

Additionally, the collaboration will witness the launch of the Supply Chain Academy, an initiative intended to provide and enhance knowledge related to vaccines supply chain, which will be led by an International Federation of Purchasing and Supply Management certified entity.

Dr Asma Al Mannaei, executive director, Research and Innovation Centre at DoH, said: “The four areas of collaboration between DoH and Sanofi are of extreme importance and we are hoping that hand in hand, we will be able to present successful findings that will enhance patients’ lives around the world.”

Jean-Paul Scheuer, MCO lead and GM for specialty care Sanofi Greater Gulf, said: “We hope our partnership with DoH – Abu Dhabi will address the urgent health issues facing the UAE and positively impact its healthcare sector. We look forward to sharing our expertise and working collaboratively to achieve shared goals, and serve patients, communities, and society at large.”

In other news, DOH also signed a Declaration of Collaboration with global biopharmaceutical company, MSD GCC.

Read: Department of Health – Abu Dhabi and biopharma firm MSD GCC announce collaboration